SPOTLIGHT -
Final Pearls: Changing Possibilities in MDD Management
Clinicians wrap up their discussion on novel, rapid-acting agents for major depressive disorder (MDD) with key insights and takeaways for providers.
Clinical Insights: Second Case Analysis of MDD
Clinicians expand their discussion with a second patient case, highlighting similarities and differences between cases, and particular treatment algorithms that may be helpful.
Responding With Treatment: Clinical Perspectives on First MDD Case
Experts continue their discussion of the first patient case, explaining how glutamate-modulating therapies could help improve his symptoms and outcomes.
Clinical Insights: First Case Analysis of MDD
Experts use a major depressive disorder (MDD) patient case to provide clinical insights on managing MDD, and how they would educate patients about their condition.
Examining New Agents for MDD Treatment (Esketemine)
Clinicians wrap up their discussion of three new agents approved for the treatment of major depressive disorder (MDD).
Examining New Agents for MDD Treatment (Zuranolone)
Clinicians continue their discussion of three new agents approved for the treatment of major depressive disorder (MDD).
Examining New Agents for MDD Treatment (AXS-05)
Clinicians begin their review of three new agents approved for the treatment of major depressive disorder (MDD).
Current Landscape of Rapid-Acting Therapies for MDD
Experts highlight the current and prospective therapies for patients with MDD, highlighting key similarities and differences in patient pathophysiology, drug onset of action, and overall therapeutic limitations.
Anhedonia and Cognitive Dysfunction: Glutamate Modulation's Impact
Experts discuss the impact of targeting glutamate receptors, highlighting its positive effects for patients with anhedonia.
Shifting Paradigms: The Future Role of Rapid Acting Antidepressants
Experts discuss the need to review current clinical guidelines in light of the need for rapid-acting treatment, especially as first-line treatments for some patients.
Hopeful Horizons: The Potential of Rapid Acting Therapies in MDD
Clinicians discuss the particular benefits of rapid-acting agents for major depressive disorder (MDD), highlighting the gap glutamate-modulating agents fill in targeted therapies.
Targeting Glutamate Receptors in MDD Treatment
Experts continue their discussion on the role of glutamate receptors, explaining their role in stimulating neuroplasticity and neurogenesis.
Cognitive Wellness: The Potential of Glutamate Modulation for MDD
Clinicians discuss the effects of glutamate modulation on neuroplasticity, memory, and cognitive function, highlighting their role in improving overall wellness for their patients.
Neurotransmitter Ballet: NMDA and AMPA in MDD Management
Experts highlight the role of NMDA and AMPA receptors in major depressive disorder (MDD) and how new therapies are targeting novel mechanisms of action.
Glutamate's Rapid Impact: A New Approach to MDD Management
Clinicians discuss past treatment options compared to novel glutamate-modulating agents, highlighting their rapid onset of symptom relief.
Navigating Major Depressive Disorder (MDD): The Role of Glutamate
Experts discuss the significance of glutamate in major depressive disorder, highlighting its links to neuroplasticity and stress.
Novel Drug Delivery Systems in ADHD and Take-Home Messages
Drs Stephen Faraone, Theresa Cerulli, Craig Chepke, and Andrew J. Cutler discuss novel drug delivery systems and provide take-home messages when treating an adult with ADHD.
Implications of Pharmacogenetic Testing in ADHD
Stephen Faraone, PhD; Theresa Cerulli, MD; Craig Chepke, MD, FAPA; and Andrew J. Cutler, MD, discuss implications of pharmacogenetic testing in ADHD.
Case 3: Factors Driving Treatment Selection in Adult ADHD
ADHD experts discuss factors that drive treatment selection when selecting therapy for an adult with ADHD.
Case 3: Treatment Goals in Adult ADHD
Theresa Cerulli, MD, and Andrew J. Cutler, MD, provide insight on goals of therapy for patients with ADHD.
Case 3: 24-Year-Old Patient With ADHD
Stephen Faraone, PhD, presents the case of a 24-year-old patient with ADHD.
Patient Case #2: Importance of an Integrative Approach in Adult ADHD
ADHD experts discuss the importance of an integrative approach in the treatment of adults with ADHD.
Patient Case #2: Addressing Non-Adherence and Stigma of Adult ADHD
Stephen Faraone, PhD; Theresa Cerulli, MD; Craig Chepke, MD, FAPA; and Andrew J. Cutler, MD, discuss addressing non-adherence and the stigma of ADHD.
Patient Case #2: Dealing With Comorbidities in Adult ADHD
Drs Stephen Faraone, Theresa Cerulli, Craig Chepke, and Andrew J. Cutler discuss how to deal with other comorbidities when treating an adult with ADHD.
Patient Case #2: Impressions and Challenges in Adult ADHD
Experts in psychiatry provide insight on a patient case as well as discuss challenges with ADHD.
Patient Case #2: A 23-Year-Old Patient With ADHD
Stephen Faraone, PhD, presents the case of a 23-year-old patient with ADHD.
Patient Case #1: Dealing With Treatment Delay in Adult ADHD
A panel of ADHD specialists discuss the impact of treatment delay when dealing with an adult patient.
Patient Case #1: Co-Managing ADHD
Drs Stephen Faraone, Theresa Cerulli, Craig Chepke, and Andrew J. Cutler discuss how to co-manage a patient with ADHD with other specialties.
Patient Case #1: Differentiating Between ADHD and Other Psychiatric Comorbidities
Experts in psychiatry discuss tips to differentiate between ADHD and other co-morbid psychiatric disorders.
Patient Case #1: Prompting an ADHD Consultation
Stephen Faraone, PhD; Theresa Cerulli, MD; Craig Chepke, MD, FAPA; and Andrew J. Cutler, MD, discuss factors which prompt adults for an ADHD consultation.